Cartesian Therapeutics, Inc.
General ticker "RNAC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $341.6M (TTM average)
Cartesian Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -12.7%.
Estimated limits based on current volatility of 6.7%: low 7.45$, high 8.51$
Factors to consider:
- Total employees count: 66 as of 2024
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.25$, 11.59$]
- 2026-12-31 to 2027-12-31 estimated range: [4.53$, 11.89$]
Short-term RNAC quotes
Long-term RNAC plot with estimates
Financial data
| YTD | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Operating Revenue | $38.91MM | $2.80MM |
| Operating Expenses | $82.81MM | $89.50MM |
| Operating Income | $-43.90MM | $-86.70MM |
| Non-Operating Income | $-33.24MM | $-52.79MM |
| R&D Expense | $45.10MM | $58.03MM |
| Income(Loss) | $-77.14MM | $-139.50MM |
| Taxes | $0.29MM | $-9.19MM |
| Profit(Loss)* | $-77.42MM | $-130.30MM |
| Stockholders Equity | $-6.80MM | $-126.24MM |
| Assets | $435.02MM | $296.41MM |
| Operating Cash Flow | $-23.67MM | $-73.94MM |
| Capital expenditure | $9.09MM | $5.45MM |
| Investing Cash Flow | $-8.74MM | $-5.45MM |
| Financing Cash Flow | $168.43MM | $-8.05MM |
| Earnings Per Share** | $-2.99 | $-5.02 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.